A Trial of Ipatasertib in Combination With Atezolizumab
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a single centre, proof-of-concept phase I trial of atezolizumab in combination with
ipatasertib. There are two parts to this study, the dose escalation phase (Part A) and the
dose expansion phase (Part B). Part A, will determine the maximum tolerated dose (MTD) and
recommended Phase II dose (RP2D). This will be followed by the Part B dose expansion phase to
further characterise the safety and tolerability and to assess the pharmacodynamic activity
of the combination.